XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 05, 2019
Nov. 30, 2021
Feb. 29, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Gain (loss) on equity securities still held       $ 8,000 $ 28,300 $ (28,100) $ (10,700)  
Restrictions on selling common stock, period   6 months            
Unrealized Gains       113,641   113,641   $ 65,891
Available for sale debt securities       363,700   363,700   66,000
Available for sale debt securities       63,000   63,000   204,400
Fair Value, Recurring                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Derivative instrument, current       63,200   63,200   0
Derivative financial instruments       8,600   8,600   0
Level 3 | Fair Value, Recurring                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Derivative instrument, current               0
Derivative financial instruments               0
BioCryst Pharmaceuticals, Inc. | Level 3                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Number of shares purchased (in shares)   3,846,000            
Milestone Acceleration | Level 3 | Fair Value, Recurring                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Derivative instrument, current       63,200   63,200    
Derivative financial instruments       8,600   $ 8,600    
Cytokinetics Commercial Launch Funding | Level 3                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Interest rate volatility (as a percent)           30.00%    
Risk-adjusted discount rate (as a percent)           15.20%    
Preferred Shares                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Unrealized Gains       84,241   $ 84,241   49,191
Available for sale debt securities       300,000   300,000   66,000
Available for sale debt securities       63,000   63,000   $ 187,700
Preferred Shares | Milestone Acceleration                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Unrealized Gains       $ 71,800   $ 71,800    
Preferred Shares | Debt Securities                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Number of shares purchased (in shares) 2,495              
Redemption price, percentage           2    
Preferred shares, quarterly payments           $ 15,600    
Preferred shares, fixed payment amount     $ 250,000          
Preferred shares, weighted average cost of capital           13.70%   9.50%